Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-04-29
2008-04-29
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07365053
ABSTRACT:
The present invention provides a process for selectively acylating an A82846A, A82846B, A82846C or PA-42867-A glycopeptide at the N1, N2 or N3 positions and the monoacylated compounds prepared therefrom.
REFERENCES:
patent: 4639433 (1987-01-01), Hunt et al.
patent: 4643987 (1987-02-01), Nagarajan et al.
patent: 4698327 (1987-10-01), Nagarajan et al.
patent: 5591714 (1997-01-01), Nagarajan et al.
patent: 5840684 (1998-11-01), Cooper et al.
patent: 0 435 503 (1990-12-01), None
patent: 99/56760 (1999-11-01), None
Cooper et al.,J. Antiobiotics, 49:6, 575-581 (1996) Reductive Alkylation of Glycopeptide Antibiotics: Synthesis and Antibacterial Activity.
Nagarajan et al.,J. Antibiotics, 41:10, 1430-1438 (1988) Synthesis and antibacterial activity of N-acyl vancomycins.
International Search Report PCT/US 01/04540, dtd. Oct. 24, 2001.
Thompson Richard Craig
Wilkie Stephen Charles
Zweifel Mark James
Eli Lilly and Company
Teller Roy
Tsang Cecilia J.
LandOfFree
Selective N-acylation of A82846 glygopeptides analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective N-acylation of A82846 glygopeptides analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective N-acylation of A82846 glygopeptides analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2742290